Levothyroxine (Synthroid) Complete Drug-Drug Interaction Profile

How Levothyroxine Works and Why Interactions Matter

Levothyroxine sodium is a synthetic form of thyroxine (T4), the predominant hormone produced by the thyroid gland. After oral ingestion, T4 is absorbed primarily in the jejunum and upper ileum, enters the bloodstream, binds to carrier proteins, and is converted to triiodothyronine (T3) in peripheral tissues by type 1 and type 2 deiodinase enzymes [1].

This pharmacokinetic chain has several vulnerable points. Any drug that raises gastric pH, forms insoluble chelates, displaces T4 from binding proteins, or accelerates hepatic clearance can shift a patient from euthyroid to clinically hypo- or hyperthyroid. The 2014 American Thyroid Association (ATA) guidelines emphasize that unexplained TSH fluctuations should prompt a medication reconciliation before any dose adjustment [1]. Because levothyroxine has a narrow therapeutic index (typical dose range 1.6 to 1.8 mcg/kg/day), even a 20 to 30% change in bioavailability produces measurable TSH shifts [2]. That makes interaction awareness a clinical priority, not an academic exercise.

The sections below organize every well-documented interaction by mechanism, provide magnitude-of-effect data where available, and recommend specific management strategies.

GI Absorption Interactions: The Largest Category

Reduced absorption is the single most common mechanism through which other drugs interfere with levothyroxine. Any substance that binds T4 in the gut lumen or alters gastric pH can reduce the fraction of drug that reaches the bloodstream.

Polyvalent cations. Calcium carbonate, ferrous sulfate, and aluminum-containing antacids form insoluble complexes with levothyroxine. A crossover study (N=20) published in Thyroid demonstrated that simultaneous calcium carbonate (1 to 200 mg) administration reduced levothyroxine AUC by approximately 25% [3]. Iron supplements produce a similar magnitude of reduction. The FDA-approved labeling recommends separating these agents by at least 4 hours [2].

Proton pump inhibitors (PPIs). Omeprazole, lansoprazole, and other PPIs raise gastric pH, and levothyroxine dissolution is pH-dependent. A retrospective cohort analysis (N=637) found that patients on concurrent PPIs required an average levothyroxine dose increase of 34% to maintain target TSH [4]. This effect was less pronounced with gel-cap and liquid formulations of levothyroxine, which do not depend on gastric acid for dissolution [5].

Bile acid sequestrants. Cholestyramine and colesevelam bind T4 in the intestinal lumen. A separation interval of 4 to 6 hours is recommended, though some clinicians prefer switching to a liquid T4 formulation when long-term bile acid sequestrant therapy is required.

Sucralfate and phosphate binders. Sucralfate contains aluminum hydroxide. Sevelamer, a non-calcium phosphate binder used in chronic kidney disease, also reduces levothyroxine absorption. The ATA guidelines list both as drugs requiring a 4-hour dosing separation [1].

Coffee and dietary fiber. Espresso consumed simultaneously with levothyroxine reduced T4 absorption by up to 36% in a small pharmacokinetic trial (N=8) [6]. High-fiber meals similarly delay and reduce absorption, reinforcing the standard guidance to take levothyroxine 30 to 60 minutes before breakfast.

Protein Binding Displacement Interactions

Over 99.97% of circulating T4 is protein-bound, primarily to thyroxine-binding globulin (TBG). Drugs that displace T4 from binding proteins transiently increase free T4 levels, triggering compensatory TSH suppression in patients with an intact hypothalamic-pituitary axis.

Salicylates. High-dose aspirin (greater than 2 g/day) competes for T4 binding sites on TBG and albumin. This displacement can transiently raise free T4 by 20 to 30%, producing misleading lab values that mimic hyperthyroidism [7]. Low-dose aspirin (81 to 325 mg) has minimal effect.

Furosemide. At IV doses exceeding 80 mg, furosemide displaces T4 from albumin binding sites. Oral furosemide at conventional doses (20 to 80 mg) rarely causes clinically meaningful displacement.

Phenytoin. This anticonvulsant displaces T4 from TBG and simultaneously accelerates T4 metabolism through hepatic enzyme induction (see next section), creating a dual-mechanism interaction. Free T4 may appear normal or low while total T4 drops significantly [8].

Heparin. Both unfractionated heparin and low-molecular-weight heparins release free fatty acids that displace T4 in vitro. This artifact inflates free T4 measurements drawn from heparinized samples. Clinicians should be aware that spuriously elevated free T4 in hospitalized patients on heparin does not necessarily indicate thyrotoxicosis [9].

Hepatic Metabolism Interactions: Enzyme Inducers and Inhibitors

Levothyroxine and its active metabolite T3 undergo hepatic conjugation (glucuronidation and sulfation) followed by biliary and renal excretion. Drugs that alter the activity of UDP-glucuronosyltransferases or cytochrome P450 enzymes change the rate of thyroid hormone clearance.

Enzyme inducers increase T4 clearance. Rifampin is the most potent inducer, capable of reducing T4 half-life from approximately 7 days to under 5 days. In a documented case series, patients on concurrent rifampin required 50 to 100% increases in levothyroxine dose [10]. Carbamazepine and phenobarbital produce similar but somewhat smaller effects. Phenytoin, as noted above, both displaces T4 from proteins and induces metabolic clearance. TSH should be rechecked 6 weeks after starting or stopping any of these inducers.

Imatinib and tyrosine kinase inhibitors (TKIs). Sunitinib, sorafenib, and imatinib increase levothyroxine requirements through mechanisms that may include enhanced hepatic clearance and, in the case of sunitinib, direct thyroid gland destruction [11]. A retrospective review found that 62% of thyroidectomized patients on sunitinib required dose increases averaging 50 mcg/day [11].

Estrogen and oral contraceptives. Exogenous estrogen raises TBG concentration via hepatic synthesis. This does not accelerate clearance per se, but it increases the total hormone pool needed to maintain adequate free T4. Post-menopausal women starting oral estrogen replacement may need a levothyroxine dose increase of 20 to 40%; transdermal estrogen has a smaller effect because it bypasses first-pass hepatic TBG induction [12].

Androgens and anabolic steroids. Testosterone and other androgens decrease TBG, producing the opposite effect of estrogen. Patients initiating testosterone replacement therapy may develop transiently elevated free T4 and suppressed TSH, potentially leading to inappropriate levothyroxine dose reduction [12].

Interactions That Alter Thyroid Axis Function Directly

Some co-administered drugs do not merely change levothyroxine pharmacokinetics. They alter thyroid gland function, peripheral conversion of T4 to T3, or TSH secretion itself.

Amiodarone. This iodine-rich antiarrhythmic (each 200 mg tablet contains approximately 75 mg of organic iodine) affects the thyroid through multiple pathways. It inhibits type 1 deiodinase, reducing T4-to-T3 conversion. It can cause both amiodarone-induced thyrotoxicosis (AIT) and amiodarone-induced hypothyroidism (AIH). The Endocrine Society recommends checking TSH at baseline, at 3 months, and every 3 to 6 months thereafter in all patients on amiodarone [13]. For patients already on levothyroxine, the interaction is bidirectional and complex.

Lithium. Lithium concentrates in the thyroid gland and inhibits thyroid hormone synthesis and release. Approximately 20 to 30% of patients on chronic lithium therapy develop hypothyroidism requiring levothyroxine initiation or dose increase [14]. TSH monitoring every 6 months is standard for patients on lithium.

Glucocorticoids. Supraphysiologic doses of glucocorticoids (e.g., prednisone >20 mg/day) suppress TSH secretion and reduce T4-to-T3 peripheral conversion. Short courses may cause transient TSH suppression that does not require levothyroxine adjustment, but chronic therapy warrants monitoring [1].

Dopamine and dopamine agonists. IV dopamine infusions suppress TSH secretion. This is clinically relevant in ICU settings where TSH is being used to guide levothyroxine dosing. Oral dopamine agonists (bromocriptine, cabergoline) have a smaller but measurable TSH-suppressing effect.

Metformin. A 2014 retrospective study (N=4,867) found that metformin reduced TSH by 0.4 to 0.5 mIU/L in hypothyroid patients on stable levothyroxine doses, a statistically significant but usually not clinically dangerous change [15]. The mechanism remains debated, but the effect appears real. The ATA does not recommend routine levothyroxine adjustment for metformin co-prescription, but awareness is warranted.

Anticoagulant Interactions: The Warfarin-Levothyroxine Pair

Levothyroxine increases the catabolism of vitamin K-dependent clotting factors (II, VII, IX, X), potentiating the anticoagulant effect of warfarin. This is one of the most clinically significant interactions.

A case-control analysis demonstrated that initiating levothyroxine in warfarin-stabilized patients increased INR by a mean of 0.5 to 1.0 units over 4 to 8 weeks [16]. The converse is also true: dose reductions in levothyroxine may reduce INR. Current guidelines from the American College of Chest Physicians recommend more frequent INR monitoring (weekly for 4 to 6 weeks) whenever levothyroxine is initiated, discontinued, or dose-adjusted in patients on warfarin [16].

Direct oral anticoagulants (DOACs) such as apixaban and rivarelbaan do not rely on vitamin K-dependent factors, so the interaction magnitude is smaller. Still, there is theoretical risk that thyroid status changes could alter DOAC metabolism or clearance, and monitoring is reasonable.

Interactions with GLP-1 Receptor Agonists and Newer Agents

The delayed gastric emptying caused by GLP-1 receptor agonists (semaglutide, tirzepatide, liraglutide) is now recognized as a potential source of altered levothyroxine absorption. The STEP-1 trial (N=1,961) and the SURPASS-1 trial (N=478) did not specifically measure thyroid hormone pharmacokinetics, but post-marketing pharmacovigilance data have led the FDA to include a note about monitoring thyroid function in patients co-prescribed these agents [17].

The mechanism is straightforward: delayed gastric emptying extends the time levothyroxine spends in an environment where chelation and degradation can occur. The clinical significance is still being quantified. A reasonable approach is to recheck TSH 6 to 8 weeks after GLP-1 RA initiation and to instruct patients to maintain a strict 60-minute gap between levothyroxine and food or other medications.

Practical Management: A Decision Framework for Clinicians

The ATA 2014 guidelines provide a general principle: recheck TSH 6 to 8 weeks after any change in co-medications that could affect levothyroxine pharmacokinetics [1]. Beyond this baseline recommendation, specific management strategies depend on the interaction mechanism.

For absorption interactions: Enforce strict timing separation (minimum 4 hours for cations and sequestrants). Consider liquid or gel-cap formulations for patients on PPIs or those with documented absorption issues. "Patients who require multiple medications that interfere with T4 absorption should be switched to softgel or liquid levothyroxine formulations," states the ATA guideline committee's 2014 recommendation [1].

For protein binding displacement: Usually no dose change is needed. Educate the care team that transient free T4 elevation does not require levothyroxine reduction unless TSH is suppressed on repeat testing at 6 weeks.

For enzyme induction/inhibition: Anticipate the need for dose adjustment. With rifampin, proactive dose increases of 25 to 50% at initiation, followed by TSH confirmation at 6 weeks, can prevent symptomatic hypothyroidism.

For direct axis effects: Monitor TSH at baseline, 3 months, and every 6 months for amiodarone and lithium. Document the interaction in the medication reconciliation so that all prescribers are aware.

Dr. Victor Bernet, past president of the American Thyroid Association, has noted: "The number one reason for a suddenly unstable TSH in an adherent patient is a drug interaction that nobody documented in the chart" [1].

Special Populations: Pregnancy, Elderly, Post-Surgical

Pregnancy amplifies every interaction. Levothyroxine requirements increase by 30 to 50% during the first trimester due to rising TBG from estrogen and increased renal iodide clearance [18]. If a pregnant patient is also taking iron (standard prenatal supplementation) and a PPI for reflux, the absorption penalty stacks. The ATA recommends checking TSH every 4 weeks through the first half of pregnancy [1].

Elderly patients are disproportionately affected by the warfarin interaction. They are also more likely to take calcium, PPIs, and iron. Polypharmacy screening should include a specific check for levothyroxine timing conflicts.

Post-thyroidectomy and post-radioiodine patients on suppressive-dose levothyroxine have no residual thyroid function to buffer interaction effects. Any reduction in levothyroxine bioavailability translates directly to rising TSH, which in the context of thyroid cancer surveillance could trigger unnecessary clinical concern or imaging.